{
    "title": "108_s1974",
    "content": "The \"Medicare Preservation and Drug Price Fairness Act\" repeals the authority to negotiate prices and the Comparative Cost Adjustment (CCA) program, as well as addresses pharmaceutical market access. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 amends the Federal Food, Drug, and Cosmetic Act to include importation of prescription drugs. Pharmacists, wholesalers, and qualifying individuals are now included in the importation process, ensuring compliance with relevant sections of the Act. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 amends the Federal Food, Drug, and Cosmetic Act to include importation of prescription drugs by pharmacists and wholesalers. Amendments include changes to subsections (c) and (d) regarding importation procedures and requirements. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 amends the Federal Food, Drug, and Cosmetic Act to include importation of prescription drugs by pharmacists and wholesalers. The amendments involve changes to subsections (c) and (d) related to importation procedures and requirements, including certification from importers or manufacturers that products meet Act requirements. Additionally, paragraphs (4) through (9) are redesignated as paragraphs (3) through (8). The amendments to the Federal Food, Drug, and Cosmetic Act include changes to importation procedures and requirements for prescription drugs. Importers are required to conduct testing unless the product is a prescription drug subject to specific technologies. Wholesalers are exempt from testing requirements. Additionally, limitations on importation designated by the Secretary are removed. The amendments to the Federal Food, Drug, and Cosmetic Act involve changes to importation procedures for prescription drugs. Importers must conduct testing unless the product is a prescription drug subject to specific technologies. Wholesalers are exempt from testing requirements, and limitations on importation designated by the Secretary are eliminated. Subsection (g) is modified by removing references to counterfeit products, and subsection (i)(1) requires the Secretary to conduct a study on imports permitted under subsection (a). The amendments to the Federal Food, Drug, and Cosmetic Act involve changes to importation procedures for prescription drugs. Importers must conduct testing unless the product is a prescription drug subject to specific technologies. Wholesalers are exempt from testing requirements, and limitations on importation designated by the Secretary are eliminated. Subsection (g) is modified by removing references to counterfeit products, and subsection (i)(1) requires the Secretary to conduct a study on imports permitted under subsection (a). In subsection (k)(2), regulations under subsection (a) are to be complied with, and the incidence of misbranded or adulterated shipments is to be determined. The timeframe for compliance is specified as 18 months after the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The Federal Food, Drug, and Cosmetic Act is amended to include new definitions and requirements for counterfeit-resistant technologies to prevent counterfeiting of drugs. Subsections (l) and (m) are removed, and new provisions are added to ensure compliance with packaging requirements for drugs subject to specific technologies. Title V of the Federal Food, Drug, and Cosmetic Act is amended to include new requirements for counterfeit-resistant technologies in drug packaging. Title V of the Federal Food, Drug, and Cosmetic Act is amended to include new requirements for counterfeit-resistant technologies in drug packaging, specifically in Section 505B. The Secretary must mandate that drug packaging includes overt optically variable counterfeit-resistant technologies or equivalent security technologies. These technologies must be visible to the naked eye, similar to those used in securing US currency, and easily identifiable without additional devices. Manufacturers of drugs must ensure secure manufacturing and distribution processes, incorporating non-visible covert security features. Packaging standards require multiple elements to incorporate technologies to prevent counterfeiting, including blister packs, labels, seals, bottles, and boxes. Shipments of drugs must include labels on shipping containers with specified technologies. The text chunk discusses the requirement for shipping containers to have labels with specified technologies to verify the authenticity of drug shipments. It also mentions the repeal of certain provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. SEC. 5 amends the definition of a qualifying plan under section 1860D-3(a) and SEC. 6 repeals the MA Regional Plan Stabilization Fund. SEC. 6 repeals the MA Regional Plan Stabilization Fund and makes amendments to the Social Security Act. SEC. 7 repeals Health Savings Accounts under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. The amendments made by this Act will be effective as if included in the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. If any amendment is repealed, the provision will be applied as if the amendment never existed."
}